Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Big pharma - Caught on Camera

Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'

China has pulled ahead of the United States in clinical drug development and supply chain, two of six domains measured in a June Cure Innovation Index survey, even as Big Pharma signs billion-dollar deals for Chinese-developed medicines.

Benzinga

‘It is okay not to be okay’: NFL legend Terrell Davis joins growing roster of athletes partnering with big pharma to raise health awareness

The hall-of-famer has partnered with Teva to raise awareness on Tardive Dyskinesia, a chronic movement disorder. He’s in good company with Serena & co.

Fortune

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

MarketBeat

Merck Just Made a Big Bet on a New Cancer Growth Engine

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.

MarketBeat

Some health care CEOs are praising TrumpRx for empowering consumers to compare drug prices

Also: All the news and watercooler chat from Fortune.

Fortune

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.

MarketBeat

6 Therapies for Chronic Pain That Big Pharma Doesn’t Want You to Know

Chronic pain affects millions of retirees, often stemming from arthritis, back problems, or long‑term injuries. Big Pharma promotes medications as the primary solution, but drugs...

Saving Advice

TrumpRx Brings Pfizer Into the Green—Is It a Buy?

Pfizer entered into a major agreement with the U.S. government to produce more affordable drugs for Americans. However, the stock’s outlook is still cloudy.

MarketBeat

Big Pharma’s retreat: Is NHS pricing behind investor pullbacks?

Multinational pharmaceutical firms are pulling pack or pausing investments in the UK, blaming a lack of competitive drug pricing.

Euronews

The AI drug breakthrough is taking a long time to arrive for reasons that may have little to do with the technology’s limits

“No matter how much data you have, human biology is still a mystery,” one analyst said.

Fortune

Ozempic Is The New Botox And Big Pharma Is Printing Billions

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1 market could surpass $150 billion…

Benzinga

Tylenol In The Firing Line: RFK Jr. Autism Study Triggers Outrage, Market Rout And Big Pharma Panic

RFK Jr.'s autism study linking Tylenol in pregnancy to disorders sparks Big Pharma panic, political backlash and a fierce debate over corporate power.

International Business Times UK

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Breaking the Bottleneck: How Verseon is Rewriting the Future of Drug Discovery Beyond Pharma's Limits

Verseon is transforming drug discovery with physics-based design, breaking pharma's limits to deliver safer, faster treatments across major diseases.

MarketBeat

Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly

Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats.

The Independent UK

Laura Loomer’s MAGA critics accuse her of being funded by Big Pharma

‘I do not work for Big Pharma. I work in support of President Trump on the outside of the administration,’ Loomer tells The Independent

Benzinga

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

Imagine you stepped into the dimly lit hospital meeting room to pitch a new cancer‑diagnostic deal. You flick through slides powered by Palantir Technologies Inc.'s (NASDAQ:PLTR) Foundry platform, showcasing data transparency and precision that would make legacy pharma pipelines look prehistoric.

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Why two-time founder and MacArthur Genius Daphne Koller sees a future where humans 'create together with the machines'

"The future has to be getting people to partner well and create together with the machines," Koller told Fortune.

Latin Times

RFK Jr. Admitting Big Pharma Paid Trump '$100 Million' Leaves Internet Stunned: 'Was That a Fraudian Slip?'

RFK Jr. told Americans President Trump cannot be bought while also revealing Trump accepted $100 million from Big Pharma.

Salon

Eat the rich films have run their course

The bland satire in "Death of a Unicorn" makes its message unappetizing; there are tastier options

Fortune

Moderna and Novavax shares plunge after key FDA official steps down, citing discord with RFK Jr. who he says 'wishes subservient confirmation of his misinformation and lies'

Massive cuts to personnel and funding within the Department of Health and Human Services presents a headache for vaccine approval and development, analysts say.

The Conversation

Australia’s ‘coercive’ news media rules are the latest targets of US trade ire

As the United States recalibrates its trade policies to combat what the Trump administration sees as “unfair” treatment by other countries, two significant industries have complained to US regulators about their treatment in Australia.

MarketBeat

3 Stocks With Ironclad Balance Sheets for Long-Term Stability

Check out these three stocks with balance sheets that have a case for being among the strongest in the entire stock market.

Fortune

My son’s rare disease diagnosis spurred me to ditch Big Pharma for a biotech startup

Most individuals diagnosed with a rare disease won’t live to become teenagers or adults. I knew what I had to do.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations